Video

Reporting from ESMO Congress 2019, Philippe Ruszniewski comments on results of 3 studies that evaluated the effects of the addition of radioembolisation to peptide receptor radionuclide therapy in patients with advanced neuroendocrine tumours (NETs), doubling a dose of lanreotide in patients with pancreatic or midgut NETs who progressed on conventional dosage, and the efficacy and safety of novel tyrosine kinase inhibitor surufatinib in well-differentiated advanced extrapancreatic NETs.

Oncology Meeting Resources

Major Sponsors

AstraZeneca Bristol-Myers Squibb MSD Servier

Main Sponsors

Bayer Healthcare Boehringer Ingelheim Daiichi Sankyo ipsen Janssen logo Pfizer Oncology Roche